Psychotic Major Depression
Corcept completes enrollment in third Phase 3 study for treating psychotic major depression
Published in Healthcare Mergers, Acquisitions and Ventures Week, December 16th, 2006
The company expects to announce the results in late February 2007.
A total of 441 patients have been enrolled in Study 06, a randomized, double-blind, placebo-controlled trial, at 40 sites in the United States and 5 sites in Europe. The primary endpoint is the proportion of patients with at least a 50% improvement in the Brief Psychiatric Rating Scale Positive Symptom Subscale (BPRS PSS)...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Mergers, Acquisitions and Ventures Week
More Articles from Healthcare Mergers, Acquisitions and Ventures Week
- Acute Bronchitis
Virginia Commonwealth researchers report antibiotics unnecessary for bronchitis - Age-Related Macular Degeneration
Cellgate initiates phase I clinical study for eye disease - Age-Related Macular Degeneration
Study evaluates Macular Health supplement in dry age-related macular degeneration - Alzheimer Disease
Coalition calls U.S. FDA's new focus on neurological diseases a positive first step - Amyotrophic Lateral Sclerosis
InnoCentive posts $1 million seeker challenge for biomarker discovery - Ankylosing Spondylitis
Data shows Enbrel provides sustained clinical improvements for people with ankylosing spondylitis - More from this issue of Healthcare Mergers, Acquisitions and Ventures Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
